Journal of visualized experiments : JoVE
Cure8 research brief
Why This Matters
AIEC is linked to IBD pathogenesis but is defined by lab assays rather than clear genetic markers. This paper presents a practical assay to detect cell invasion even when isolates are resistant to gentamicin, which could help researchers and labs identify invasive E. coli strains from IBD patients.
Who Should Pay Attention
Researchers, microbiologists, and clinical laboratory staff working on IBD‑associated bacteria or diagnostic assay development.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This JoVE article describes a lab assay that replaces gentamicin with amikacin to measure and visualize invasion of epithelial cells by adherent‑invasive Escherichia coli (AIEC), a bacterium implicated in IBD.
The method quantifies invasion by recovering intracellular colony‑forming units after killing extracellular bacteria with amikacin and can also visualize intracellular bacteria by immunostaining and confocal microscopy.
The protocol is presented as a workaround for gentamicin resistance in isolates from patients who have received antibiotics; amikacin is argued to remain extracellular to host cells and to kill extracellular, including some multidrug‑resistant, E. coli strains.
The paper frames the assay as useful for classifying AIEC phenotypically and for screening clinical isolates for cell‑invasive behavior. The article is an experimental methods paper (JoVE video/article) focused on laboratory technique rather than clinical outcomes.
It may be directly useful to researchers or clinical labs that study bacterial invasion or characterize isolates from IBD patients, but it does not provide clinical guidance or patient‑level findings.
Keep In Mind
The source is a JoVE methods article presented at the abstract/full‑text level here; it describes lab methodology and rationale but does not report clinical validation or patient outcome data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of visualized experiments : JoVE
AuthorsField S, Kim J, Orth K +1 more
Study typeVideo Audio media, im, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 3, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Sutterella Inhibition of Aryl hydrocarbon receptor Interleukin-22 signaling and worsening of intestinal inflammation byspecies.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
Responses of intestinal organoids to infection by resemble symptoms observed in Crohn's disease Mycobacterium avium .
The work models how Mycobacterium avium can provoke epithelial inflammation similar to Crohn's disease, pointing to possible molecular links between infection and CD-like pathology that could guide future research.
A preliminary study of HMGB1 defense in Crohn's disease
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...